In modern ophthalmology, the concept of irreversible vision loss is increasingly being re-examined. Advances in clinical research and technology are challenging long-standing assumptions about cellular degeneration, shifting attention toward the possibility that certain retinal cells may remain viable, though functionally inactive. This evolving perspective is beginning to reshape how vision impairment is understood—and, potentially, how it is treated.
Dr. Maka Gogiashvili, MD, DSc, is a professor of ophthalmology and the founder of the “New Technologies – MaGo” International Eye Clinic. Trained under renowned ophthalmologist Svyatoslav Fyodorov, she further advanced her scientific expertise through a year of work and research with Academician Natalya Bekhtereva, the distinguished neurophysiologist and founder of the Institute of the Human Brain. Building on this foundation, she has developed a non-surgical method known as Magotherapy, focused on cellular regeneration. The approach is supported by 12 international patents and has been applied in more than 10,000 cases worldwide, including patients previously considered untreatable.
A Shift in Clinical Perspective
Globally adopted approaches to vision loss often assume irreversible cellular damage. Dr. Gogiashvili’s methodology is grounded in a different premise: that some affected cells may remain viable, though inactive.
This concept is based on the theory of parabiosis—a physiological state in which cells are not dead, but alive, though “dormant,” and therefore not functioning. Originally introduced by neurophysiologist Nikolai Vvedensky, the theory suggests that, under certain conditions, cellular activity may be restored.
“We’re not replacing biological function,” says Dr. Gogiashvili. “We’re not trying to replace nature; we’re giving it a chance to restart.”
She emphasizes that this approach is used exclusively at the MaGo clinic, where a proprietary, patented method is employed to identify and activate the body’s underused biological resources—capacities that exist in every person, though to different extents. The clinic also offers an early, personalized prognosis, often from the first consultation, estimating potential vision improvement. For international patients, this assessment can be done remotely, based on medical exams performed in their home country.
Magotherapy applies this concept through a non-invasive process designed to stimulate metabolic activity in retinal cells. According to the clinic, the method does not rely on surgery, pharmaceuticals, or corrective lenses, but instead uses innovative equipment to activate cellular processes along neural pathways.
The treatment is designed to improve oxygenation and nutrient delivery at the cellular level—processes that occur within milliseconds (approximately two-thousandths of a second)—potentially restoring functional signaling between the eye and the brain. This rapid physiological response helps explain why patients may begin to experience measurable improvements in vision within as little as one hour of the procedure. Dr. Gogiashvili emphasizes that vision is not solely an optical process but a neurological one:
“The eye transmits information, but interpretation happens in the brain. When this pathway is disrupted, visual clarity is affected.”
The method is applied across a wide range of conditions — including retinal dystrophies, nystagmus, glaucoma, and post-surgical complications — because in magotherapy, what determines outcomes is the organism’s own healing resources, regardless of the disease’s etiology, duration, severity, or the patient’s age. Treatment protocols are individualized, based on diagnostic assessments and patient-specific factors.
According to the clinic, results are perceived by patients before the full treatment course is complete. On the first visit, a prognosis is established based on the organism’s available healing resources. On the second day, a test magotherapy procedure is performed — and within one hour, patients typically report noticeably improved vision, characterized by increased flashes of light. As treatment progresses, the frequency and duration of these perceptions grow as more cells resume activity. This rapid response is attributed to the restoration of cellular metabolism occurring in 1/2000th of a second, within which the brain processes the impulse and restores a sharp visual image, explaining the positive outcomes observed even in conditions previously considered untreatable. The non-invasive nature of the method is a defining feature. Without pharmacological or surgical intervention, the risks of complications and extended recovery time are eliminated, as magotherapy is a physiological, entirely natural method.
Dr. Gogiashvili notes that treatment outcomes are monitored over time, with an emphasis on slowing or stabilizing disease progression. According to Dr. Gogiashvili’s clinical observations, magotherapy halts or slows the progression of disease. Because the method is entirely physiological, it can be continued for as long as needed until the desired result is achieved. The clinic reports long-term follow-up data spanning more than two decades — supported by scientific documentation, clinical records, and a photo gallery available on their YouTube channel: Magotherapy Eye Clinic | Dr. Maka Gogiashvili.
A key component of the approach is personalization—adapting treatment protocols to individual physiological responses. This is particularly relevant in cases where standard treatments offer limited options.
Looking Ahead
As ophthalmology continues to evolve, regenerative approaches are gaining attention for their potential to transform existing treatment models.”
Dr. Gogiashvili advocates for earlier diagnosis and proactive care, emphasizing the importance of timely intervention:
“As long as a cell remains viable, there is potential for recovery. Act before vision is completely lost because every single day matters when it comes to awakening dormant cells.”
